CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Onyx Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.

1:17-cv-00449

Overview

Case Number 1:17-cv-00449
Filing Date 2017-04-20
Status Terminated
Termination Date 2018-02-14
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Teva Pharmaceutical Industries Ltd Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

1 Attorneys Listed

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Plaintiff

Onyx Therapeutics, Inc. Operating Company

Represented By

4 Attorneys Listed

Will C. Autz

Email: wautz@omm.com

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Margaret A. O'Boyle

Email: moboyle@omm.com

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

No Co-Pending Disputes Detected in Current Index

There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.

Patents Involved

No asserted patent numbers detected in initial docket filings yet.

Docket Entries

(36 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - iled against Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2125819.) - filed by Onyx Therapeutics, Inc. (Attachments: # 1 Exhibits A - I, # 2 Civil Cover Sheet)(rwc) (Entered: 04/20/2017)

Entry #1 • 2017-04-20
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 04/20/2017)

Entry #2 • 2017-04-20
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/7/17. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 1/20/2020. (rwc) (Entered: 04/20/2017)

Entry #3 • 2017-04-20
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) - SEE ATTACHED FORM. (rwc) (Entered: 04/20/2017)

Entry #4 • 2017-04-20
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amgen Inc., Corporate Parent Onyx Pharmaceuticals, Inc. for Onyx Therapeutics, Inc. filed by Onyx Therapeutics, Inc. (rwc) (Entered: 04/20/2017)

Entry #5 • 2017-04-20
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc